ISSN Print 2500–1094
ISSN Online 2542–1204
BIOMEDICAL JOURNAL OF PIROGOV UNIVERSITY (MOSCOW, RUSSIA)
Copyright: © 2026 by the authors. Licensee: Pirogov University.
This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (CC BY).
This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (CC BY).
ORIGINAL RESEARCH
Platelet receptor gene polymorphisms and altered platelet aggregation in patients with COVID-19 and type 2 diabetes mellitus
About authors
1 South Ural State Medical University, Chelyabinsk, Russia
2 Chelyabinsk Regional Clinical Hospital, Chelyabinsk, Russia
3 Regional Clinical Hospital No. 3, Chelyabinsk, Russia
Correspondence should be addressed: Semen O. Zotov
Vorovsky, 64, Chelyabinsk, 454092, Russia; ur.xednay@7002znemes
About paper
Author contribution: Osikov MV, Antonov VN — study planning; Zotov SO — literature review, data acquisition, analysis, and interpretation.
Compliance with ethical standards: the study was approved by the Ethics Committee of the South Ural State Medical University (protocol No. 4 dated May 24, 2021, protocol No. 2 dated March 5, 2026). All patients submitted the informed consent.
Received: 2026-05-18
Accepted: 2026-07-15
Published online: 2026-07-28
|
Fig. Hemostasis indicators in patients with COVID-19-DAD and T2D, carriers of the hemostasis factor gene mutant polymorphisms: rs5918 of the gene ITGB3 (А); rs1126643 of the gene ITGA2 (B); rs6065 of the gene GP1BA (C). V (inducer) — rate of induced platelet aggregation; * — significant differences (p < 0.05) from carriers of the “wild type” genotype; # — from carriers of heterozygote
Table 1. Main clinical, laboratory, and instrumental indicators of the studied groups at admission
Note: * — significant (p < 0.05) differences from group 1.
Table 2. Genotype abundance when analyzing polymorphisms of the genes ITGB3, GP1B1 и ITGA2 in individuals with COVID-19-DAD and T2D
Note: * — significant (p < 0.05) differences from group 1; # — from group 2; 0 — wild type genotype; I — heterozygote; II — mutant homozygote.
Table 3. Characteristics of patients with COVID-19-DAD and T2D based on the abundance of ITGB3, GP1B1, and ITGA2 polymorphisms
Note: * — significant (p < 0.05) differences; I — heterozygote; II — mutant homozygote.
Table 4**. Induced platelet aggregation in individuals with COVID-19-DAD and T2D depending on the ITGB3, ITGA2, and GP1B1 polymorphisms on day 7, Ме(Q25; Q75)
Note: * — significant (p < 0.05) differences from the homozygous non-mutant variant within the group based on the Kruskal‒Wallis test with the Dunn’s test; # — from the heterozygous variant within the group; 0 — wild type genotype; I — heterozygote; II — mutant homozygote.
